The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 21)
Improved Biomarkers and Clinical Outcome Measures, 2016
There is a great need to identify Parkinson's disease (PD) in its earliest stages when interventions may prevent or slow neural degeneration. Given that the earliest brain pathology of PD occurs outside of the motor system, namely in the olfactory bulbs (brain regions that detect smell) and the brainstem (brain region that controls involuntary functions), we are probing the functi...
Research Grant, 2016
Currently, there is no single test that can be used to confirm a diagnosis of Parkinson's disease (PD) or a biomarker that can track its progression. People with PD have many abnormalities in the autonomic nervous system (controls involuntary function), which may be related to Parkinson's changes outside of the brain. A new device called the SudoScan, which measures changes in swe...
Researchers: Ronald B. Postuma, MD, MSc
Research Grant, 2015
CAPTURE-PD: Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease
Parkinson's disease is a progressive neurodegenerative disorder that does not only affect movement but also the autonomic nervous system. Since most people start developing the disease in their sixties, the ongoing global trend toward population aging is expected to result in increasing numbers of people with Parkinson's disease. Therefore, there is an urgent nee...
Therapeutic Pipeline Program, 2015
Constipation and gastroparesis (slow stomach emptying) are common non-motor symptoms of Parkinson's disease (PD). These symptoms cause troublesome gastrointestinal issues and can impair the absorption of and, response to, Parkinson's medications, such as levodopa. Unfortunately, there are FDA-approved treatments for slow stomach emptying in PD, and rigorously te...
Researchers: Leslie Jameleh Cloud, MD, MSc
Research Grant, 2013
Evaluation of Alpha-synuclein Immunohistochemical Methods for the Detection of Lewy-type Synucleinopathy in Gastrointestinal Biopsies
Lewy bodies, which consist mainly of aggregated protein alpha-synuclein, are a pathological hallmark of Parkinson's disease (PD). Lewy bodies in the enteric nerves, which govern gastrointestinal function and are accessible to biopsy, may be a biomarker candidate for PD. However, the two available studies on the use of gastrointestinal biopsies for the detection of ...